 Rohit Katial
Concepts (381)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 37 | 2022 | 2039 | 4.550 |
Why?
| | Anti-Asthmatic Agents | 13 | 2022 | 336 | 3.660 |
Why?
| | Aspirin | 11 | 2018 | 330 | 3.280 |
Why?
| | Hypersensitivity | 8 | 2018 | 278 | 3.160 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 154 | 2.720 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 30 | 2.640 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 94 | 2.440 |
Why?
| | Sinusitis | 7 | 2020 | 164 | 1.810 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 324 | 1.680 |
Why?
| | Nitric Oxide | 7 | 2018 | 897 | 1.580 |
Why?
| | Rhinitis | 5 | 2018 | 121 | 1.540 |
Why?
| | Adrenal Cortex Hormones | 10 | 2022 | 510 | 1.440 |
Why?
| | Histamine Antagonists | 4 | 2011 | 19 | 1.380 |
Why?
| | Eosinophils | 11 | 2022 | 274 | 1.200 |
Why?
| | Exhalation | 2 | 2018 | 37 | 1.200 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 51 | 1.170 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 111 | 1.130 |
Why?
| | Immunotherapy | 5 | 2017 | 459 | 1.100 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 82 | 1.070 |
Why?
| | Rhinitis, Allergic | 2 | 2014 | 42 | 1.030 |
Why?
| | Nasal Polyps | 4 | 2018 | 45 | 0.930 |
Why?
| | Pancreatitis | 2 | 2012 | 106 | 0.880 |
Why?
| | Albuterol | 3 | 2010 | 107 | 0.850 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2022 | 654 | 0.840 |
Why?
| | Breath Tests | 4 | 2007 | 90 | 0.820 |
Why?
| | Androstadienes | 2 | 2010 | 102 | 0.800 |
Why?
| | Biomarkers | 7 | 2018 | 3485 | 0.790 |
Why?
| | Humans | 84 | 2022 | 114571 | 0.760 |
Why?
| | Drug Hypersensitivity | 4 | 2016 | 83 | 0.750 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 54 | 0.700 |
Why?
| | Biological Products | 2 | 2018 | 134 | 0.700 |
Why?
| | Biological Therapy | 1 | 2017 | 28 | 0.640 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 27 | 0.620 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 18 | 0.610 |
Why?
| | Allergy and Immunology | 1 | 2016 | 57 | 0.590 |
Why?
| | Vaccination | 3 | 2012 | 1086 | 0.570 |
Why?
| | Antibodies, Monoclonal | 3 | 2018 | 1294 | 0.570 |
Why?
| | Administration, Intranasal | 6 | 2011 | 88 | 0.560 |
Why?
| | Sputum | 3 | 2013 | 287 | 0.540 |
Why?
| | Anaphylaxis | 1 | 2016 | 139 | 0.510 |
Why?
| | Practice Guidelines as Topic | 6 | 2017 | 1541 | 0.490 |
Why?
| | Allergens | 5 | 2016 | 498 | 0.490 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 550 | 0.490 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 99 | 0.460 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 388 | 0.440 |
Why?
| | Eosinophilia | 4 | 2019 | 179 | 0.440 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 27 | 0.410 |
Why?
| | Disease Progression | 4 | 2022 | 2486 | 0.400 |
Why?
| | Vaccines | 2 | 2004 | 338 | 0.390 |
Why?
| | Mast Cells | 2 | 2013 | 120 | 0.380 |
Why?
| | Acetates | 1 | 2010 | 114 | 0.370 |
Why?
| | Nose | 1 | 2009 | 53 | 0.370 |
Why?
| | Quinolines | 1 | 2010 | 140 | 0.360 |
Why?
| | Laryngismus | 1 | 2008 | 4 | 0.360 |
Why?
| | Adult | 29 | 2019 | 32077 | 0.360 |
Why?
| | Leukotriene E4 | 1 | 2008 | 32 | 0.350 |
Why?
| | Vocal Cords | 1 | 2008 | 29 | 0.350 |
Why?
| | Immunity, Cellular | 2 | 2007 | 303 | 0.340 |
Why?
| | Skin Tests | 2 | 2005 | 141 | 0.330 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1419 | 0.320 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 59 | 0.320 |
Why?
| | Respiratory Tract Infections | 2 | 2004 | 290 | 0.320 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 200 | 0.320 |
Why?
| | Severity of Illness Index | 4 | 2017 | 2847 | 0.320 |
Why?
| | Middle Aged | 23 | 2019 | 28854 | 0.310 |
Why?
| | Double-Blind Method | 5 | 2022 | 1681 | 0.300 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.300 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 343 | 0.300 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 123 | 0.300 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 6 | 0.290 |
Why?
| | Female | 31 | 2022 | 63070 | 0.290 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 230 | 0.290 |
Why?
| | Male | 29 | 2018 | 60817 | 0.290 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 4 | 0.290 |
Why?
| | Nebulizers and Vaporizers | 3 | 2015 | 84 | 0.280 |
Why?
| | Anesthetics, Local | 1 | 2005 | 87 | 0.280 |
Why?
| | Analgesia | 1 | 2005 | 98 | 0.270 |
Why?
| | Chronic Disease | 5 | 2018 | 1648 | 0.270 |
Why?
| | Serum Sickness | 1 | 2004 | 6 | 0.270 |
Why?
| | Syphilis | 1 | 2004 | 36 | 0.270 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 70 | 0.270 |
Why?
| | Bioterrorism | 1 | 2004 | 19 | 0.270 |
Why?
| | Antigens, Bacterial | 2 | 2002 | 129 | 0.270 |
Why?
| | Bupropion | 1 | 2004 | 39 | 0.270 |
Why?
| | Cytokines | 3 | 2016 | 1964 | 0.270 |
Why?
| | Exanthema | 1 | 2004 | 68 | 0.270 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 62 | 0.260 |
Why?
| | Cockroaches | 1 | 2003 | 28 | 0.260 |
Why?
| | Administration, Inhalation | 3 | 2016 | 667 | 0.260 |
Why?
| | Research Design | 1 | 2009 | 938 | 0.260 |
Why?
| | Recurrence | 2 | 2017 | 988 | 0.250 |
Why?
| | Alternaria | 1 | 2002 | 8 | 0.240 |
Why?
| | Glycoproteins | 2 | 2002 | 336 | 0.240 |
Why?
| | Lolium | 1 | 2002 | 4 | 0.240 |
Why?
| | Signal Transduction | 2 | 2016 | 4890 | 0.240 |
Why?
| | Treatment Outcome | 9 | 2018 | 9190 | 0.240 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 17 | 0.230 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 76 | 0.230 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 17 | 0.230 |
Why?
| | Poaceae | 1 | 2002 | 76 | 0.230 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 47 | 0.230 |
Why?
| | Interferon-gamma | 3 | 2016 | 771 | 0.220 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 23 | 0.220 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 54 | 0.220 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 71 | 0.220 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 99 | 0.220 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 1004 | 0.220 |
Why?
| | Tuberculin | 1 | 2001 | 6 | 0.220 |
Why?
| | Hypersensitivity, Delayed | 1 | 2001 | 56 | 0.220 |
Why?
| | Tuberculin Test | 1 | 2001 | 35 | 0.220 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 13 | 0.210 |
Why?
| | Young Adult | 9 | 2019 | 10987 | 0.210 |
Why?
| | United States | 5 | 2018 | 12551 | 0.210 |
Why?
| | Immunoglobulin E | 4 | 2017 | 353 | 0.210 |
Why?
| | Reference Values | 4 | 2007 | 852 | 0.200 |
Why?
| | Adolescent | 11 | 2019 | 18658 | 0.200 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 269 | 0.200 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2001 | 127 | 0.200 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.190 |
Why?
| | Algorithms | 4 | 2020 | 1502 | 0.190 |
Why?
| | Child | 8 | 2019 | 17859 | 0.190 |
Why?
| | Drug Combinations | 2 | 2010 | 303 | 0.190 |
Why?
| | Lung | 2 | 2007 | 3558 | 0.190 |
Why?
| | Histamine | 2 | 2011 | 68 | 0.180 |
Why?
| | Chickenpox Vaccine | 1 | 1999 | 72 | 0.180 |
Why?
| | Tosyl Compounds | 1 | 1998 | 21 | 0.180 |
Why?
| | Theophylline | 1 | 1998 | 59 | 0.180 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 77 | 0.180 |
Why?
| | Bacterial Capsules | 2 | 2012 | 29 | 0.180 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 45 | 0.180 |
Why?
| | Lamiaceae | 1 | 1997 | 2 | 0.170 |
Why?
| | Artemisia | 1 | 1997 | 9 | 0.170 |
Why?
| | Plants, Medicinal | 1 | 1997 | 20 | 0.170 |
Why?
| | Mycobacterium tuberculosis | 1 | 2001 | 281 | 0.170 |
Why?
| | Aged | 6 | 2019 | 20218 | 0.170 |
Why?
| | Primary Health Care | 1 | 2008 | 1531 | 0.170 |
Why?
| | Benzamides | 1 | 2018 | 186 | 0.160 |
Why?
| | Lymphocytosis | 1 | 1997 | 11 | 0.160 |
Why?
| | Aging | 1 | 2007 | 1708 | 0.160 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 22 | 0.160 |
Why?
| | Pyrroles | 1 | 2018 | 203 | 0.160 |
Why?
| | Leukotrienes | 1 | 2016 | 40 | 0.160 |
Why?
| | Allergists | 1 | 2016 | 15 | 0.160 |
Why?
| | Quality of Life | 3 | 2014 | 2230 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 105 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 380 | 0.150 |
Why?
| | Interleukin-4 | 3 | 2013 | 215 | 0.150 |
Why?
| | Bacterial Toxins | 1 | 1997 | 109 | 0.150 |
Why?
| | Venoms | 1 | 2016 | 34 | 0.150 |
Why?
| | Canada | 1 | 2017 | 325 | 0.150 |
Why?
| | Interleukins | 2 | 2013 | 237 | 0.150 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 43 | 0.150 |
Why?
| | Insecta | 1 | 2016 | 65 | 0.150 |
Why?
| | Drugs, Generic | 1 | 2015 | 17 | 0.140 |
Why?
| | Cardiac Tamponade | 1 | 1994 | 16 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 1998 | 489 | 0.140 |
Why?
| | Papilloma | 1 | 1994 | 56 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 461 | 0.140 |
Why?
| | Bronchial Diseases | 1 | 1994 | 36 | 0.140 |
Why?
| | Pentamidine | 1 | 1994 | 4 | 0.140 |
Why?
| | Herpesvirus 3, Human | 1 | 1999 | 392 | 0.140 |
Why?
| | Epinephrine | 1 | 2016 | 186 | 0.140 |
Why?
| | Tumor Virus Infections | 1 | 1994 | 66 | 0.140 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 35 | 0.140 |
Why?
| | Gallium Radioisotopes | 1 | 1994 | 23 | 0.130 |
Why?
| | Papillomaviridae | 1 | 1994 | 126 | 0.130 |
Why?
| | Phosphorylation | 2 | 2016 | 1728 | 0.130 |
Why?
| | Animals | 7 | 2017 | 34687 | 0.130 |
Why?
| | Bronchiectasis | 1 | 1994 | 96 | 0.130 |
Why?
| | Basophils | 2 | 2013 | 71 | 0.130 |
Why?
| | Aerosols | 3 | 2001 | 161 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1994 | 119 | 0.130 |
Why?
| | Olfaction Disorders | 1 | 2013 | 36 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 884 | 0.120 |
Why?
| | Rabies Vaccines | 1 | 2012 | 1 | 0.120 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 5 | 0.120 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.120 |
Why?
| | Drug Resistance | 1 | 2013 | 185 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2015 | 291 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1808 | 0.120 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 28 | 0.120 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 172 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 728 | 0.120 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1004 | 0.110 |
Why?
| | Receptors, Histamine | 1 | 2011 | 6 | 0.110 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 23 | 0.110 |
Why?
| | Papillomavirus Infections | 1 | 1994 | 242 | 0.110 |
Why?
| | Immunity, Humoral | 1 | 2012 | 102 | 0.110 |
Why?
| | Cost of Illness | 1 | 2014 | 296 | 0.110 |
Why?
| | History, 19th Century | 1 | 2011 | 59 | 0.110 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 43 | 0.110 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 234 | 0.110 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 140 | 0.110 |
Why?
| | Fluticasone | 1 | 2010 | 85 | 0.110 |
Why?
| | Health Surveys | 2 | 2012 | 500 | 0.100 |
Why?
| | Phenotype | 2 | 2017 | 2842 | 0.100 |
Why?
| | History, 20th Century | 1 | 2011 | 309 | 0.100 |
Why?
| | Cyclopropanes | 1 | 2010 | 87 | 0.100 |
Why?
| | Receptors, IgG | 1 | 2009 | 75 | 0.100 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 7 | 0.100 |
Why?
| | Congresses as Topic | 1 | 2011 | 202 | 0.100 |
Why?
| | Sulfides | 1 | 2010 | 98 | 0.090 |
Why?
| | Chemokines, CC | 1 | 2009 | 34 | 0.090 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 52 | 0.090 |
Why?
| | Bone Marrow | 2 | 2013 | 263 | 0.090 |
Why?
| | Clinical Competence | 1 | 2016 | 935 | 0.090 |
Why?
| | Administration, Oral | 1 | 2011 | 796 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 185 | 0.090 |
Why?
| | Medication Adherence | 1 | 2014 | 570 | 0.090 |
Why?
| | Interleukin-13 | 1 | 2009 | 127 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2016 | 3249 | 0.090 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 23 | 0.090 |
Why?
| | Adenosine | 1 | 2009 | 217 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2018 | 5045 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 68 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2009 | 336 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 694 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 989 | 0.080 |
Why?
| | Health Status | 1 | 2012 | 782 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 518 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 462 | 0.080 |
Why?
| | Flushing | 1 | 2005 | 2 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2009 | 795 | 0.070 |
Why?
| | Administration, Topical | 1 | 2005 | 155 | 0.070 |
Why?
| | Penicillin G | 1 | 2004 | 8 | 0.070 |
Why?
| | Infant | 1 | 2018 | 8096 | 0.070 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 36 | 0.070 |
Why?
| | Acute Disease | 1 | 2008 | 993 | 0.070 |
Why?
| | Mutation | 1 | 2016 | 3378 | 0.070 |
Why?
| | Biomedical Research | 1 | 2011 | 585 | 0.070 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 3 | 0.070 |
Why?
| | Clostridium botulinum | 1 | 2004 | 5 | 0.070 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 3 | 0.070 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 8 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 21 | 0.070 |
Why?
| | Francisella tularensis | 1 | 2004 | 14 | 0.070 |
Why?
| | Yersinia pestis | 1 | 2004 | 23 | 0.070 |
Why?
| | Child, Preschool | 1 | 2018 | 9651 | 0.070 |
Why?
| | Diarrhea | 1 | 2005 | 176 | 0.070 |
Why?
| | Placebos | 2 | 2018 | 212 | 0.070 |
Why?
| | Food Contamination | 1 | 2003 | 24 | 0.060 |
Why?
| | Insect Control | 1 | 2003 | 12 | 0.060 |
Why?
| | Classification | 1 | 2003 | 21 | 0.060 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 65 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1083 | 0.060 |
Why?
| | Headache | 1 | 2004 | 154 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2016 | 11642 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2004 | 78 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 230 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 64 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2008 | 648 | 0.060 |
Why?
| | Disaster Planning | 1 | 2004 | 82 | 0.060 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 17 | 0.060 |
Why?
| | Comorbidity | 2 | 2018 | 1645 | 0.060 |
Why?
| | Pain Measurement | 1 | 2005 | 528 | 0.060 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 31 | 0.060 |
Why?
| | Consumer Product Safety | 1 | 2002 | 18 | 0.060 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 12 | 0.060 |
Why?
| | Menstruation | 1 | 2002 | 33 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 1994 | 2191 | 0.060 |
Why?
| | Drug Tolerance | 1 | 2002 | 152 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6818 | 0.060 |
Why?
| | Mycobacterium avium | 1 | 2001 | 19 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 134 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 7029 | 0.050 |
Why?
| | Plant Extracts | 1 | 2002 | 173 | 0.050 |
Why?
| | Ultrasonic Therapy | 1 | 2000 | 20 | 0.050 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 408 | 0.050 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 82 | 0.050 |
Why?
| | Pregnancy | 1 | 2011 | 5267 | 0.050 |
Why?
| | Gastroesophageal Reflux | 1 | 2002 | 227 | 0.050 |
Why?
| | Inflammation | 1 | 2010 | 2442 | 0.050 |
Why?
| | Phenylcarbamates | 1 | 1998 | 2 | 0.050 |
Why?
| | Neutrophils | 2 | 2017 | 1340 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 1209 | 0.050 |
Why?
| | Uricosuric Agents | 1 | 1998 | 6 | 0.050 |
Why?
| | Public Health | 1 | 2003 | 442 | 0.050 |
Why?
| | Probenecid | 1 | 1998 | 11 | 0.050 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 7 | 0.050 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 19 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1229 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 913 | 0.050 |
Why?
| | Leukotriene Antagonists | 1 | 1998 | 42 | 0.040 |
Why?
| | Methacholine Chloride | 1 | 2018 | 44 | 0.040 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 9 | 0.040 |
Why?
| | Pokeweed Mitogens | 1 | 1998 | 8 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 48 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 31 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2379 | 0.040 |
Why?
| | Concanavalin A | 1 | 1998 | 83 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 429 | 0.040 |
Why?
| | Immunocompetence | 1 | 1998 | 46 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1997 | 24 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 590 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 70 | 0.040 |
Why?
| | Equipment Design | 2 | 2015 | 533 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1997 | 56 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 138 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 219 | 0.040 |
Why?
| | Organophosphonates | 1 | 1998 | 97 | 0.040 |
Why?
| | Herpes Simplex | 1 | 1998 | 100 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4950 | 0.040 |
Why?
| | Cross Reactions | 1 | 1997 | 163 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2013 | 4281 | 0.040 |
Why?
| | Superantigens | 1 | 1997 | 71 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 362 | 0.040 |
Why?
| | Enterotoxins | 1 | 1997 | 85 | 0.040 |
Why?
| | Immunoblotting | 1 | 1997 | 352 | 0.040 |
Why?
| | Drug Interactions | 1 | 1998 | 402 | 0.040 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 218 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4741 | 0.040 |
Why?
| | Prognosis | 1 | 2005 | 3546 | 0.040 |
Why?
| | Immunization | 1 | 1999 | 410 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 488 | 0.040 |
Why?
| | Pollen | 1 | 1997 | 127 | 0.040 |
Why?
| | Workflow | 1 | 2017 | 111 | 0.040 |
Why?
| | JC Virus | 1 | 2016 | 31 | 0.040 |
Why?
| | Indoles | 1 | 1998 | 348 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2015 | 19 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2015 | 32 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 1999 | 542 | 0.040 |
Why?
| | IgA Deficiency | 1 | 1994 | 6 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1366 | 0.040 |
Why?
| | Pericarditis | 1 | 1994 | 13 | 0.040 |
Why?
| | Biopsy | 2 | 2011 | 1048 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 1999 | 1101 | 0.030 |
Why?
| | Sulfonamides | 1 | 1998 | 455 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2555 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 155 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1994 | 155 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 191 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 713 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 9078 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 5 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 21 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 371 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 443 | 0.030 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 52 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 379 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2013 | 143 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 327 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 734 | 0.030 |
Why?
| | Flow Cytometry | 1 | 1997 | 1164 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 347 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 605 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1998 | 1242 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1994 | 256 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2011 | 99 | 0.030 |
Why?
| | Efficiency | 1 | 2012 | 96 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 410 | 0.030 |
Why?
| | Nasal Mucosa | 1 | 2011 | 95 | 0.030 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 3 | 0.030 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.030 |
Why?
| | Lymphopenia | 1 | 2010 | 55 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 160 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 329 | 0.020 |
Why?
| | Cats | 1 | 2009 | 209 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 435 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 211 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 290 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2887 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 349 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 308 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 447 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 610 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 706 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 942 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1496 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2187 | 0.020 |
Why?
| | ROC Curve | 1 | 2005 | 489 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5137 | 0.020 |
Why?
| | Brain | 1 | 2016 | 2711 | 0.020 |
Why?
| | Spectrophotometry | 1 | 2001 | 66 | 0.010 |
Why?
| | Rheology | 1 | 2001 | 98 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 169 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2607 | 0.010 |
Why?
| | Particle Size | 1 | 2001 | 385 | 0.010 |
Why?
| | Cytosine | 1 | 1998 | 49 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 80 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15429 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2005 | 4408 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|